Edition:
India

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

3.99USD
22 Nov 2017
Change (% chg)

$0.04 (+1.01%)
Prev Close
$3.95
Open
$4.01
Day's High
$4.01
Day's Low
$3.90
Volume
37,278
Avg. Vol
58,474
52-wk High
$6.63
52-wk Low
$3.31

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Anavex Life Sciences Corp :Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients.Anavex Life Sciences Corp - ‍ANAVEX2-73 demonstrates desirable PK/PD properties.Anavex Life Sciences Corp - ‍clear concentration-effect relationship between ANAVEX2-73 and study measurements​.  Full Article

Anavex signs material transfer agreement with Biogen
Wednesday, 28 Sep 2016 

Anavex Life Sciences :Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73.  Full Article

Anavex Life Sciences says drug shows efficacy to support disease modification in Parkinson’s disease
Thursday, 22 Sep 2016 

Anavex Life Sciences Corp : Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints . Data indicates that ANAVEX 2-73 is well tolerated .Anavex life sciences’ drug shows efficacy to support potential disease modification in Parkinson’s disease.  Full Article

Anavex reports Q3 loss per share $0.06
Friday, 12 Aug 2016 

Anavex Life Sciences Corp : Anavex reports fiscal third quarter 2016 financial results . Q3 loss per share $0.06 . SEC staff recently advised company's legal counsel that staff did not intend to recommend enforcement action by commission .SEC staff advise relates to investigation previously described in company's 2015 report on form 10-K.  Full Article

Anavex confirms data from Phase 2a study of ANAVEX 2-73 in Alzheimer’s patients presented at AAIC 2016
Friday, 29 Jul 2016 

Anavex Life Sciences Corp : Anavex "remains dedicated" to advancing ANAVEX 2-73 and will be reporting new data to investors as it becomes available . Anavex confirms data from phase 2a study of ANAVEX 2-73 in alzheimer's patients presented at AAIC 2016 .Anavex confirms that there has been no change with regards to its science, data or fundamentals of company.  Full Article

Anavex announces U.S. FDA orphan drug designation to anavex 2-73
Friday, 20 May 2016 

Anavex Life Sciences Corp :Announces U.S. FDA orphan drug designation to anavex 2-73 for the treatment of rett syndrome.  Full Article

BRIEF-Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73

* Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients